EUVIMEDEUVIMED entdecken
Crossref

Tranexamic Acid-Based Polymeric Micellar Hydrogel for Enhanced Dermal Delivery and Melanin Reduction

Srishty Jaiswal, Bakr Ahmed, Srishti Naryal, Maneesha Rana, Simrandeep Kaur, Indu Pal Kaur iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c01470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Srishty Jaiswal und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India. Hauptthemen laut MEDLINE: Tranexamic Acid, Melanins, Hydrogels, Polymers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Bristol-Myers Squibb, Department of Science and Technology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral and intralesional tranexamic acid (TXA), used in melasma treatment, pose systemic and invasive risks, while topical TXA suffers from poor permeability (logP = -1.6) and retention. The current study aimed to develop a topically effective polymeric micelles (PMs) based product incorporating 5% w/v TXA for deeper skin permeation and efficient melanocyte targeting. Developed PMs were novel in terms of: (i) composition, (ii) high drug loading of 250% with respect to the polymeric matrix, and (iii) transparent system. TXA-PMs had a particle size of 47.0 ± 3.6 nm, exhibited an entrapment efficiency of 81 ± 1.4%, and were transformed into a hydrogel (Hgel) for better skin retention by incorporating 0.5% Carbopol 934P. TXA-PMs Hgel had a pH of 5.7 and demonstrated favorable Newtonian pseudoplastic behavior, diffusion-controlled Higuchi release (>97%) up to 48 h, enhanced skin permeation (93% versus 74% observed with the marketed product), and retention (160% versus marketed product). On the other hand, free TXA in the Hgel matrix and the marketed product were released within 8 h. Three tier safety of TXA-PMs Hgel was demonstrated in in vitro cytotoxicity, in vivo acute toxicity, and biocompatibility tests. It substantially reduced melanin concentration (>50% inhibition) in B16F10 melanoma cell lines in comparison to free TXA Hgel (34%). The accelerated stability studies (6 months) revealed no significant change in the prepared formulations. TXA-PMs Hgel thus offers a promising therapeutic approach for melasma treatment as indicated by its enhanced permeation, stay in skin, and significant reduction in melanin content. Further, the production method is simple, industry amenable, and scalable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidMelaninsHydrogelsPolymersAnimalsMicellesMiceAdministration, CutaneousSkinSkin AbsorptionMelanocytesHumansDrug CarriersParticle SizeDrug Delivery SystemsDrug LiberationMelanosis

Stichwörter der Autor:innen

drug retentionin vivo skin permeationmelanoma cellsmelasmananoparticlesthree-tier safety

Substanzen

Tranexamic AcidMelaninsMicellesHydrogelsPolymersDrug Carriers

Autor:innen und Institutionen

  • University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.

ORCID-Profile: Indu Pal Kaur

Förderung

  • Bristol-Myers Squibb
  • Department of Science and Technology, Ministry of Science and Technology, India

Zitieren

APA

Jaiswal, S., Ahmed, B., Naryal, S., Rana, M., Kaur, S., & Kaur, I. P. (2025). Tranexamic Acid-Based Polymeric Micellar Hydrogel for Enhanced Dermal Delivery and Melanin Reduction. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01470

Vancouver

Jaiswal S, Ahmed B, Naryal S, Rana M, Kaur S, Kaur IP. Tranexamic Acid-Based Polymeric Micellar Hydrogel for Enhanced Dermal Delivery and Melanin Reduction. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01470

BibTeX
@article{Jaiswal2025,
  author = {Jaiswal, Srishty and Ahmed, Bakr and Naryal, Srishti and Rana, Maneesha and Kaur, Simrandeep and Kaur, Indu Pal},
  title = {Tranexamic Acid-Based Polymeric Micellar Hydrogel for Enhanced Dermal Delivery and Melanin Reduction},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c01470}
}
Kostenlos starten →